Cargando…
The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study
BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723652/ https://www.ncbi.nlm.nih.gov/pubmed/23875823 http://dx.doi.org/10.1186/1550-2783-10-33 |
_version_ | 1782278312553349120 |
---|---|
author | Jenkins, Nathaniel DM Housh, Terry J Johnson, Glen O Traylor, Daniel A Bergstrom, Haley C Cochrane, Kristen C Lewis,, Robert W Schmidt, Richard J Cramer, Joel T |
author_facet | Jenkins, Nathaniel DM Housh, Terry J Johnson, Glen O Traylor, Daniel A Bergstrom, Haley C Cochrane, Kristen C Lewis,, Robert W Schmidt, Richard J Cramer, Joel T |
author_sort | Jenkins, Nathaniel DM |
collection | PubMed |
description | BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation on the recovery of isometric strength and selected non-invasive indicators of muscle damage. METHODS: A double-blinded, placebo-controlled, crossover design was used to study eighteen men (mean ± SD age = 22.2 ± 3.1 yrs; body mass = 80.3 ± 15.7 kg) who participated in two randomly-ordered conditions separated by a washout period. The ANA condition consisted of consuming 6–12 mg anatabine per day for 10 days, while testing took place during days 7–10. The placebo (PLA) condition was identical except that the PLA supplement contained no ANA. Maximal voluntary isometric peak torque (PT) of the forearm flexors, arm circumference, hanging joint angle, and subjective pain ratings were measured before (PRE), immediately after (POST), and 24, 48, and 72 h after six sets of 10 maximal, eccentric isokinetic forearm flexion muscle actions. Resting heart rate and blood pressure were measured at PRE and 72 h in each condition. RESULTS: For PT, hanging joint angle, arm circumference, and subjective pain ratings, there were no condition x time (p > 0.05) interactions, there were no main effects for condition (p > 0.05), but there were main effects for time (p < 0.001). There were no condition x time (p > 0.05) interactions and no main effects for condition (p > 0.05) or time (p > 0.05) for blood pressure or resting heart rate. CONCLUSIONS: ANA supplementation had no effect on the recovery of muscle strength, hanging joint angle, arm swelling, or subjective pain ratings after a bout of maximal eccentric exercise in the forearm flexors. Therefore, ANA may not be beneficial for those seeking to improve recovery from heavy eccentric exercise. Future studies should examine the effects of ANA on the pro-inflammatory cytokine responses to exercise-induced muscle damage and the chronic low-grade inflammation observed in obese and elderly individuals. |
format | Online Article Text |
id | pubmed-3723652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37236522013-07-26 The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study Jenkins, Nathaniel DM Housh, Terry J Johnson, Glen O Traylor, Daniel A Bergstrom, Haley C Cochrane, Kristen C Lewis,, Robert W Schmidt, Richard J Cramer, Joel T J Int Soc Sports Nutr Research Article BACKGROUND: Anatabine (ANA), a minor tobacco alkaloid found in the Solanaceae family of plants, may exhibit anti-inflammatory activity, which may be useful to aid in recovery from exercise-induced muscle damage. The purpose of this study, therefore, was to examine the effects of ANA supplementation on the recovery of isometric strength and selected non-invasive indicators of muscle damage. METHODS: A double-blinded, placebo-controlled, crossover design was used to study eighteen men (mean ± SD age = 22.2 ± 3.1 yrs; body mass = 80.3 ± 15.7 kg) who participated in two randomly-ordered conditions separated by a washout period. The ANA condition consisted of consuming 6–12 mg anatabine per day for 10 days, while testing took place during days 7–10. The placebo (PLA) condition was identical except that the PLA supplement contained no ANA. Maximal voluntary isometric peak torque (PT) of the forearm flexors, arm circumference, hanging joint angle, and subjective pain ratings were measured before (PRE), immediately after (POST), and 24, 48, and 72 h after six sets of 10 maximal, eccentric isokinetic forearm flexion muscle actions. Resting heart rate and blood pressure were measured at PRE and 72 h in each condition. RESULTS: For PT, hanging joint angle, arm circumference, and subjective pain ratings, there were no condition x time (p > 0.05) interactions, there were no main effects for condition (p > 0.05), but there were main effects for time (p < 0.001). There were no condition x time (p > 0.05) interactions and no main effects for condition (p > 0.05) or time (p > 0.05) for blood pressure or resting heart rate. CONCLUSIONS: ANA supplementation had no effect on the recovery of muscle strength, hanging joint angle, arm swelling, or subjective pain ratings after a bout of maximal eccentric exercise in the forearm flexors. Therefore, ANA may not be beneficial for those seeking to improve recovery from heavy eccentric exercise. Future studies should examine the effects of ANA on the pro-inflammatory cytokine responses to exercise-induced muscle damage and the chronic low-grade inflammation observed in obese and elderly individuals. BioMed Central 2013-07-22 /pmc/articles/PMC3723652/ /pubmed/23875823 http://dx.doi.org/10.1186/1550-2783-10-33 Text en Copyright © 2013 Jenkins et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jenkins, Nathaniel DM Housh, Terry J Johnson, Glen O Traylor, Daniel A Bergstrom, Haley C Cochrane, Kristen C Lewis,, Robert W Schmidt, Richard J Cramer, Joel T The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title | The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title_full | The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title_fullStr | The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title_full_unstemmed | The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title_short | The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
title_sort | effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723652/ https://www.ncbi.nlm.nih.gov/pubmed/23875823 http://dx.doi.org/10.1186/1550-2783-10-33 |
work_keys_str_mv | AT jenkinsnathanieldm theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT houshterryj theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT johnsongleno theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT traylordaniela theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT bergstromhaleyc theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT cochranekristenc theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT lewisrobertw theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT schmidtrichardj theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT cramerjoelt theeffectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT jenkinsnathanieldm effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT houshterryj effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT johnsongleno effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT traylordaniela effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT bergstromhaleyc effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT cochranekristenc effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT lewisrobertw effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT schmidtrichardj effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy AT cramerjoelt effectsofanatabineonnoninvasiveindicatorsofmuscledamagearandomizeddoubleblindplacebocontrolledcrossoverstudy |